Related Experiment Video
Updated: Apr 11, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
EGFR-targeted therapies based on antibody engineering and nanotechnology for colorectal cancer
Xingxing Shang1, Ziyi Zhang1, Tao Wu1
1School of Pharmaceutical Sciences, Fudan University, Shanghai Engineering Research Center of Immunotherapeutics, Shanghai, 201203, China.
Abstract:
Epidermal Growth Factor Receptor (EGFR) is crucial for cell proliferation and survival, and has emerged as a promising therapeutic target for colorectal cancer (CRC). Anti-EGFR monoclonal antibodies (mAbs) have demonstrated success in various clinical practice in CRC patients. However, they are only effective in patients with RAS wild-type, and more importantly, most patients eventually develop resistance to anti-EGFR therapy due to the mutations of the effector molecules in EGFR downstream signaling pathways or/and the activation of compensatory feedback loop signaling, which limits the long-term efficacy of anti-EGFR mAbs. Advances in antibody engineering and nanotechnology have brought new hope for cancer treatment, particularly through bi-/tri-specific antibodies, antibody-drug conjugates(ADCs), and antibody-functionalized nanoparticles(AFNPs), which can simultaneously inhibit the activation of EGFR and its compensatory pathways-or even directly eradicate cancer cells bypassing EGFR-mediated signaling-these innovations hold promise for addressing drug resistance and leading to better response rates of EGFR-targeted therapy in CRC. In this review, we provide an overview of the design strategy of EGFR-targeted therapies based on antibody engineering and nanotechnology for CRC using a mechanistic framework, focusing on analyzing the optimization strategies for representative drugs or studies and their potential in overcoming heterogeneous drug resistance in CRC, in order to provide useful information for researchers developing EGFR-targeted drugs for CRC.
Insights
New antibody engineering and nanotechnology strategies offer hope for overcoming resistance to Epidermal Growth Factor Receptor (EGFR) therapies in colorectal cancer (CRC). These innovations aim to improve treatment efficacy for patients with advanced CRC.
Area of Science:
- Oncology
- Biotechnology
- Nanomedicine
Background:
- Epidermal Growth Factor Receptor (EGFR) is a key target for colorectal cancer (CRC) therapy.
- Current anti-EGFR monoclonal antibodies (mAbs) show efficacy but are limited by resistance mechanisms.
- Resistance arises from downstream pathway mutations and compensatory signaling, reducing long-term treatment benefits.
Purpose of the Study:
- To review novel EGFR-targeted therapies utilizing antibody engineering and nanotechnology for CRC.
- To analyze strategies for overcoming drug resistance in EGFR-targeted CRC treatment.
- To provide insights for developing next-generation EGFR-targeted drugs for CRC.
Main Methods:
- Review of recent advances in antibody engineering (bi-/tri-specific antibodies, antibody-drug conjugates) and nanotechnology (antibody-functionalized nanoparticles).
- Mechanistic analysis of how these innovations target EGFR and compensatory pathways.
- Evaluation of strategies to address heterogeneous drug resistance in CRC.
Main Results:
- Novel approaches like antibody-drug conjugates and antibody-functionalized nanoparticles can overcome resistance.
- Simultaneous inhibition of EGFR and compensatory pathways enhances therapeutic outcomes.
- Bypassing EGFR-mediated signaling offers alternative eradication strategies for resistant cells.
Conclusions:
- Antibody engineering and nanotechnology represent promising avenues for next-generation EGFR-targeted CRC therapies.
- These innovations have the potential to address intrinsic and acquired resistance to anti-EGFR treatments.
- Further research and development in these areas could significantly improve CRC patient response rates and long-term survival.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:09Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Published on: April 6, 2015
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:38Mitogens and the Cell Cycle
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...